Individualized treatment selection in patients with head and neck cancer: Do molecular markers meet the challenge?

Journal of Clinical Oncology

Volumn 26, Issue 19, 2008, Pages 3114-3116

  Singh, Bhuvanesh ^a   Pfister, David G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; MESSENGER RNA; MOLECULAR MARKER; PLATINUM; PROTEIN P16; PROTEIN P53; TAXANE DERIVATIVE; TUMOR MARKER;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMOSENSITIVITY; CHROMOSOME 11Q; CHROMOSOME 3Q; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE FREE SURVIVAL; EDITORIAL; GENE EXPRESSION; GENETIC ANALYSIS; GENOME ANALYSIS; HEAD AND NECK CARCINOMA; HUMAN; IN VITRO STUDY; LARYNGECTOMY; LUNG CANCER; MEDICAL INFORMATION; ONCOGENE; ONCOLOGY; OROPHARYNX CANCER; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RADIATION RESPONSE; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TREATMENT INDICATION; TREATMENT RESPONSE; UTERINE CERVIX CANCER; WART VIRUS; GENETICS; HEAD AND NECK TUMOR; MULTIMODALITY CANCER THERAPY; PATIENT CARE PLANNING; RISK FACTOR; SURVIVAL;

COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; PATIENT CARE PLANNING; RISK FACTORS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 49249124135     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.7298     Document Type: Editorial

References (55)

1. National Comprehensive Cancer Network Practice Guidelines: Head and Neck Cancer (v.1.2007). http://www.nccn.org/professionals/physician_gls/pdf/head-and- neck.pdf
2. Pfister DG, Laurie SA, Weinstein GS, et al: American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol 24:3693-3704, 2006
3. Forastiere AA, Goepfert H, Maor M, et al: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091-2098, 2003
4. Pignon JP, Bourhis J, Domenge C, et al: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three metaanalyses of updated individual data: MACH-NC Collaborative Group: Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355:949-955, 2000
5. Wolf GT, Fisher SG: Effectiveness of salvage neck dissection for advanced regional metastases when induction chemotherapy and radiation are used for organ preservation. Laryngoscope 102:934-939, 1992
6. Lefebvre JL, Chevalier D, Luboinski B, et al: Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organisation for Research and Treatment of Cancer phase III trial: EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88:890-899, 1996
7. Urba S, Wolf G, Eisbruch A, et al: Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: A new treatment paradigm. J Clin Oncol 24:593-598, 2006
8. Worden FP, Urba S, Bradford C, et al: One cycle of induction chemotherapy (IC) in advanced oropharyngeal cancer (SCCOP) to select patients for organ preservation (OP). J Clin Oncol 23:503s, 2005 (abstr 5512)
9. Pfister DG, Ridge JA: Induction chemotherapy for larynx preservation: Patient selection or therapeutic effect? J Clin Oncol 24:540-543, 2006
10. Vermorken JB, Remenar E, van Herpen C, et al: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695-1704, 2007
11. Posner MR, Hershock DM, Blajman CR, et al: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705-1715, 2007
12. Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al: Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 23:8636-8645, 2005
13. Kumar B, Cordell K, Lee DJ, et al: EGFR, p16, HPV titer, BCLXL and p53, sex and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 26:3128-3137, 2008
14. Bockmuhl U, Schluns K, Kuchler I, et al: Genetic imbalances with impact on survival in head and neck cancer patients. Am J Pathol 157:369-375, 2000
15. Akervall J: Genomic screening of head and neck cancer and its implications for therapy planning. Eur Arch Otorhinolaryngol 263:297-304, 2006
16. Belbin TJ, Singh B, Barber I, et al: Molecular classification of head and neck squamous cell carcinoma using cDNA microarrays. Cancer Res 62:1184-1190, 2002
17. Chung CH, Parker JS, Karaca G, et al: Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 5:489-500, 2004
18. Hsu DS, Balakumaran BS, Acharya CR, et al: Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol 25:4350-4357, 2007
19. O'Regan EM, Toner ME, Smyth PC, et al: Distinct array comparative genomic hybridization profiles in oral squamous cell carcinoma occurring in young patients. Head Neck 28:330-338, 2006
20. Smeets SJ, Braakhuis BJM, Abbas S, et al: Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene 25:2558-2564, 2006
21. Wreesmann VB, Shi W, Thaler HT, et al: Identification of novel prognosticators of outcome in squamous cell carcinoma of the head and neck. J Clin Oncol 22:3965-3972, 2004
22. Foekens JA, Atkins D, Zhang Y, et al: Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 24:1665-1671, 2006
23. Wang Y, Klijn JG, Zhang Y, et al: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671-679, 2005
24. van de Vijver MJ, He YD, van't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002
25. van 't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002
26. Bradford CR, Zhu S, Ogawa H, et al: P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 25:654-661, 2003
27. Bradford CR, Zhu S, Poore J, et al: p53 mutation as a prognostic marker in advanced laryngeal carcinoma: Department of Veterans Affairs Laryngeal Cancer Cooperative Study Group. Arch Otolaryngol Head Neck Surg 123:605-609, 1997
28. Bradford CR, Zhu S, Wolf GT, et al: Overexpression of p53 predicts organ preservation using induction chemotherapy and radiation in patients with advanced laryngeal cancer: Department of Veterans Affairs Laryngeal Cancer Study Group. Otolaryngol Head Neck Surg 113:408-412, 1995
29. Ganly I, Talbot S, Carlson D, et al: Identification of angiogenesis/metastases genes predicting chemoradiotherapy response in patients with laryngopharyngeal carcinoma. J Clin Oncol 25:1369-1376, 2007
30. Homma AA, Furuta YY, Oridate NN, et al: Prognostic significance of clinical parameters and biological markers in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy. Clin Cancer Res 5:801-806, 1999
31. Lavertu PP, Adelstein DDJ, Myles JJ, et al: P53 and Ki-67 as outcome predictors for advanced squamous cell cancers of the head and neck treated with chemoradiotherapy. The Laryngoscope 111:1878-1892, 2001
32. Osman I, Sherman E, Singh B, et al: Alteration of p53 pathway in squamous cell carcinoma of the head and neck: Impact on treatment outcome in patients treated with larynx preservation intent. J Clin Oncol 20:2980-2987, 2002
33. Ashman JN, Patmore HS, Condon LT, et al: Prognostic value of genomic alterations in head and neck squamous cell carcinoma detected by comparative genomic hybridisation. Br J Cancer 89:864-869, 2003
34. Huang X, Gollin SM, Raja S, et al: High-resolution mapping of the 11q13 amplicon and identification of a gene, TAOS1, that is amplified and overexpressed in oral cancer cells. Proc Natl Acad Sci U S A 99:11369-11374, 2002
35. Rodrigo JP, Garcia LA, Ramos S, et al: EMS1 gene amplification correlates with poor prognosis in squamous cell carcinomas of the head and neck. Clin Cancer Res 6:3177-3182, 2000
36. Singh B, Reddy PG, Goberdhan A, et al: p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes Dev 16:984-993, 2002
37. Eder AM, Sui X, Rosen DG, et al: Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A 102:12519-12524, 2005
38. Kanao H, Enomoto T, Kimura T, et al: Overexpression of LAMP3/TSC403/ DC-LAMP promotes metastasis in uterine cervical cancer. Cancer Res 65:8640-8645, 2005
39. Regala RP, Weems C, Jamieson L, et al: Atypical protein kinase Ciota plays a critical role in human lung cancer cell growth and tumorigenicity. J Biol Chem 280:31109-31115, 2005
40. Brass N, Heckel D, Sahin U, et al: Translation initiation factor eIF-4gamma is encoded by an amplified gene and induces an immune response in squamous cell lung carcinoma. Hum Mol Genet 6:33-39, 1997
41. Kerley-Hamilton JS, Pike AM, Li N, et al: A p53-dominant transcriptional response to cisplatin in testicular germ cell tumor-derived human embryonal carcinoma. Oncogene 24:6090-6100, 2005
42. Dressman HK, Berchuck A, Chan G, et al: An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 25:517-525, 2007
43. Singh B, Li R, Xu L, et al: Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck 24:437-442, 2002
44. Ohie S, Udagawa Y, Aoki D, et al: Histoculture drug response assay to monitor chemoresponse. Methods Mol Med 110:79-86, 2005
45. Furukawa T, Kubota T, Hoffman RM: Clinical applications of the histoculture drug response assay. Clin Cancer Res 1:305-311, 1995
46. Schrag D, Garewal HS, Burstein HJ, et al: American Society of Clinical Oncology Technology Assessment: Chemotherapy sensitivity and resistance assays. J Clin Oncol 22:3631-3638, 2004
47. Gillison ML, Koch WM, Capone RB, et al: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92:709-720, 2000
48. Kreimer AR, Clifford GM, Boyle P, et al: Human papillomavirus types in head and neck squamous cell carcinomas worldwide: A systematic review. Cancer Epidemiol Biomarkers Prev 14:467-475, 2005
49. D'Souza G, Kreimer AR, Viscidi R, et al: Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356:1944-1956, 2007
50. Kutler DI, Wreesmann VB, Goberdhan A, et al: Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst 95:1718-1721, 2003
51. Fakhry C, Gillison ML: Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 24:2606-2611, 2006
52. Weinberger PM, Yu Z, Haffty BG, et al: Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 24:736-747, 2006
53. Strati K, Pitot HC, Lambert PF: Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model. Proc Natl Acad Sci U S A 103:14152-14157, 2006
54. Worden F, Kumar B, Lee J, et al: Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: Response an survival positively associated with HPV16 copy number. J Clin Oncol 26:3138-3146, 2008
55. Weinberger P, Kountourakis P, Sasaki C, et al: Oropharyngeal squamous cell cancers (OSCC) bearing transcriptionally active human papillomavirus (HPV) display distinct protein expression profile. J Clin Oncol 24:, 2006 (abstr 10028)